Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) and Skye Bioscience (NASDAQ:SKYE – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.
Valuation & Earnings
This table compares Alnylam Pharmaceuticals and Skye Bioscience”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alnylam Pharmaceuticals | $2.25 billion | 13.57 | -$278.16 million | ($2.17) | -108.09 |
| Skye Bioscience | N/A | N/A | -$37.65 million | ($0.72) | -1.99 |
Skye Bioscience has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alnylam Pharmaceuticals | 1 | 4 | 21 | 0 | 2.77 |
| Skye Bioscience | 0 | 0 | 6 | 0 | 3.00 |
Alnylam Pharmaceuticals presently has a consensus target price of $315.58, indicating a potential upside of 34.54%. Skye Bioscience has a consensus target price of $16.60, indicating a potential upside of 1,056.79%. Given Skye Bioscience’s stronger consensus rating and higher possible upside, analysts plainly believe Skye Bioscience is more favorable than Alnylam Pharmaceuticals.
Risk and Volatility
Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500.
Institutional and Insider Ownership
93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 3.0% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Alnylam Pharmaceuticals and Skye Bioscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alnylam Pharmaceuticals | -12.37% | N/A | -6.83% |
| Skye Bioscience | N/A | -45.78% | -37.44% |
Summary
Skye Bioscience beats Alnylam Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
About Skye Bioscience
Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
